Publication: Current Oncology
Abstract
Tamibarotene is a synthetic retinoid being investigated for pediatric and young adult patients with recurrent or refractory solid tumors, following an earlier Phase I safety study. This analysis used data from that Phase I trial, encompassing 109 samples from 22 patients receiving tamibarotene across a range of doses, to construct a population pharmacokinetic model using Phoenix NLME. Body surface area was identified as a significant covariate for clearance and both central and peripheral volumes of distribution in the final two-compartment model, which showed satisfactory predictive accuracy on validation. This population pharmacokinetic model provides a foundation for more precisely dosing tamibarotene in future pediatric and young adult oncology studies.
Author(s): Azechi T, Fukaya Y, Nitani C, Hara J, Kawamoto H, Taguchi T, Yoshimura K, Sato A, Hattori N, Ushijima T, Kimura T
Published: 2024 年 11 月 14 日
Phoenix NLME：A Foundation for Pediatric Dosing
Phoenix NLME built the first population PK model for this investigational retinoid, identifying body surface area as the key covariate for future pediatric oncology dosing. Within a Phoenix platform used by 100% of the top 20 pharma companies, Phoenix NLME can be paired with Model Designer to select, configure, and simulate models directly in the browser, guided by an AI assistant.
